Wockhardt Limited (NSE:WOCKPHARMA) disclosed its unaudited standalone and consolidated financial results for the quarter ended 30 June 2026, approved by the Board of Directors at a meeting held on 10 August 2026. Standalone revenue from operations reached Rs 561 crore, with net profit after tax of Rs 107 crore for the quarter.
Key Highlights
- Standalone revenue from operations rose to Rs 561 crore in Q1 FY27, compared with Rs 413 crore in Q1 FY26, reflecting year-on-year growth of approximately 36 per cent.
- Standalone net profit after tax stood at Rs 107 crore for Q1 FY27, up from Rs 69 crore in the corresponding quarter of the prior year.
- Standalone basic earnings per share for Q1 FY27 were Rs 6.62 (not annualised), against Rs 4.25 per share in Q1 FY26, on a face value of Rs 5 per share.
- The results were reviewed by statutory auditors MSKC and Associates LLP, who issued a limited review report with no material misstatement noted.
About the Company
Wockhardt Limited (NSE:WOCKPHARMA) is a Mumbai-headquartered pharmaceutical company operating exclusively in the pharmaceutical business segment, as confirmed in its exchange filings. The company manufactures and markets formulations across multiple geographies, including the United Kingdom, Ireland, the United States, and India. Its registered office is at D-4 MIDC, Chikalthana, Chhatrapati Sambhaji Nagar, Maharashtra.
Announcement in Detail
The Board of Directors convened on 10 August 2026, with the meeting commencing at 1:10 p.m. and concluding at 3:05 p.m. The board approved unaudited standalone and consolidated financial results for the quarter ended 30 June 2026, pursuant to Regulations 30 and 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The results were also reviewed by the Audit Committee at its meeting held on the same date.
On a standalone basis, total income for Q1 FY27 was Rs 594 crore, against Rs 438 crore in Q1 FY26. Total standalone expenses for the quarter were Rs 487 crore, yielding a profit before tax of Rs 107 crore. No exceptional items were recorded during Q1 FY27, unlike the prior-year quarter, which included an exceptional credit of Rs 25 crore. The standalone other equity excluding revaluation reserves stood at Rs 3,003 crore as of the reported balance sheet date.
Impact on Investors
Investors will note that standalone net profit of Rs 107 crore in Q1 FY27 compares favourably with Rs 69 crore in Q1 FY26, though the sequential comparison shows a decline from Rs 167 crore in Q4 FY26, which had included an exceptional credit of Rs 35 crore. The filing shows that Q1 FY27 profit before tax was Rs 107 crore with no exceptional support, whereas Q4 FY26 profit before tax of Rs 167 crore included that one-time item.
Shareholders will observe that the company's consolidated results, which encompass 28 subsidiaries and step-down subsidiaries across the UK, Ireland, the US, Brazil, Nigeria, and other geographies, were also approved and subjected to the same limited review process. The disclosed limited review report from MSKC and Associates LLP contains no qualification, which investors will note is a standard compliance outcome under Regulation 33.
Sector / Market Context
India's pharmaceutical industry is a significant contributor to global generic drug supply, with the domestic formulations market and exports both recording steady volume trends in recent years according to data published by the Pharmaceuticals Export Promotion Council of India. Antibiotic resistance and novel drug research have drawn regulatory attention globally, areas in which Wockhardt has disclosed active development programmes through its subsidiaries, including entities focused on biosimilars and antibiotics across its international network.